Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Reverse Transcriptase Inhibitor
Mniopetal D is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound demonstrates significant biological activity by blocking the reverse transcription process, which is essential in the life cycle of retroviruses. Mniopetal D is utilized in research applications focused on antiviral drug development and understanding retroviral replication mechanisms. -
Reverse Transcriptase Inhibitor
Mniopetal F is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. It effectively disrupts the replication cycle of retroviruses by hindering the reverse transcription process, making it a valuable tool in antiviral research. Mniopetal F can be utilized in studies focused on understanding viral mechanisms and developing therapeutic strategies against retroviral infections. -
Reverse Transcriptase Inhibitor
NNRT-IN-5 is a non-nucleoside reverse transcriptase inhibitor that exhibits potent antiviral activity against HIV. This compound functions by binding to the reverse transcriptase enzyme, disrupting the viral replication process. NNRT-IN-5 is primarily utilized in research to explore HIV mechanisms and develop novel therapeutic strategies targeting reverse transcriptase. -
Reverse Transcriptase Inhibitor
Mniopetal C is a reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound exhibits significant biological activity by disrupting the reverse transcription process, making it valuable for research in molecular biology and virology. Mniopetal C can be utilized in studies focused on retroviral infections and the development of antiretroviral therapies. -
Reverse Transcriptase Inhibitor
Mniopetal A is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound has demonstrated significant ability to impede the reverse transcription process, making it a valuable tool in research focused on retroviral infections and related mechanisms. Its application extends to studies investigating viral replication, cellular responses to viral entry, and therapeutic developments targeting reverse transcription pathways. -
RSV Fusion Glycoprotein Inhibitor
CGR-50 is a selective inhibitor of the respiratory syncytial virus (RSV) fusion glycoprotein, demonstrating potent activity with an EC50 of 32.6 nM against RSV A2 in HEp-2 cell lines. This compound effectively blocks RSV entry by binding to the F protein, thereby inhibiting the critical process of membrane fusion. CGR-50 is a valuable tool for research dedicated to understanding and combating RSV infections. -
RSV-F Protein Inhibitor
Sisunatovir is a potent inhibitor of the respiratory syncytial virus (RSV), targeting the RSV-F protein with IC50 values of 1.4 nM and 1.0 nM for RSV A and RSV B, respectively. It effectively inhibits RSV infection and has demonstrated the ability to reduce viral titers in the lungs of murine models. This compound is valuable for research applications focused on developing therapeutic strategies against RSV infections. -
RSV Inhibitor
Zelicapavir is an orally active inhibitor of respiratory syncytial virus (RSV) specifically targeting the viral replication process. With an effective concentration (EC50) of less than 0.4 μM, it demonstrates potent antiviral activity. This compound is applicable in research focused on understanding RSV pathogenesis and developing therapeutic strategies against RSV infections. -
RSV Inhibitor
4-Methoxycinnamaldehyde is an RSV inhibitor known for its cytoprotective activity against respiratory syncytial virus. This compound demonstrates significant efficacy in human larynx carcinoma cell lines, effectively inhibiting RSV-induced cytopathic effects with an estimated IC50 value of 0.055 μg/mL. Its properties make it a valuable tool for research into antiviral therapies and understanding RSV pathogenesis. -
RSV Inhibitor
BMS-433771 is a potent orally active inhibitor targeting respiratory syncytial virus (RSV). It demonstrates efficacy against both RSV A and B strains, with an average EC50 value of 20 nM. This compound is a valuable tool for research on respiratory tract diseases, aiding in the understanding of RSV pathology and potential therapeutic interventions. -
RSV Inhibitor
VP-14637 is a novel respiratory syncytial virus (RSV) fusion inhibitor that demonstrates potent antiviral activity with an IC50 of 1.42 ng/mL. This compound specifically targets the fusion process of RSV, making it a valuable tool for studying viral entry mechanisms and evaluating potential therapeutic strategies against RSV infections. Its high efficacy positions VP-14637 as an important reagent for researchers working on respiratory viral diseases. -
RSV Inhibitor
RSV L-protein-IN-1 is a potent inhibitor of Respiratory Syncytial Virus (RSV) that targets viral polymerase with an IC50 of 0.089 μM. It effectively disrupts RSV mRNA synthesis by inhibiting the guanylation of viral transcripts, demonstrating an EC50 of 0.021 μM. In addition to its antiviral activity, RSV L-protein-IN-1 shows moderate cytotoxicity (CC50=8.4 μM in HEp-2 cells) and has been shown to lower virus titers in mouse models of RSV infection, making it suitable for research applications aimed at understanding RSV pathogenesis and developing therapeutic strategies. -
RSV Inhibitor
JNJ 2408068 is a potent inhibitor of respiratory syncytial virus (RSV). This compound effectively suppresses the replication of RSV A and B subtypes in pulmonary tissue, demonstrating significant antiviral activity without observable toxicity in vivo. Its minimum protective dose is approximately 0.39 mg/kg, making it a valuable tool for research into RSV pathogenesis and therapeutic interventions. -
RSV Inhibitor
3,4-Di-O-caffeoyl quinic acid methyl ester is a dicaffeoyl derivative that acts as an inhibitor of respiratory syncytial virus (RSV). It demonstrates significant antiviral activity against RSV, with an IC50 value of 0.78 μg/mL. This compound is useful for research applications focused on RSV-related infections and exploring potential therapeutic options. -
RSV Inhibitor
RFI-641 is a selective inhibitor of the respiratory syncytial virus (RSV), exhibiting an IC50 of 50 nM. This compound disrupts the binding and fusion processes of the virus by targeting the viral fusion protein. RFI-641 serves as a valuable tool in RSV research, aiding studies on viral replication mechanisms and the development of therapeutic strategies against RSV infections. -
hRSV Inhibitor
hRSV-IN-1 is a potent inhibitor of the human respiratory syncytial virus (hRSV), acting primarily by interfering with viral replication. This compound exhibits significant antiviral activity, making it an important tool for research in hRSV pathogenesis and treatment strategies. hRSV-IN-1 is particularly valuable for studies focusing on respiratory viral infections and the development of therapeutic interventions. -
RSV Polymerase inhibitor
RSV L-protein-IN-3 is an inhibitor of respiratory syncytial virus (RSV) polymerase, displaying an IC50 value of 10.4 μM and an EC50 value of 2.1 μM against RSV. It demonstrates reduced cytotoxicity compared to the clinical agent Ribavirin, making it a suitable candidate for further research into treating RSV infections. This compound is valuable for studies focusing on antiviral mechanisms and drug development targeting RSV. -
RSV Inhibitor
RSV L-protein-IN-5 is a potent inhibitor of Respiratory syncytial virus (RSV), demonstrating an EC50 of 0.1 μM. This compound primarily targets the RSV polymerase, with an IC50 of 0.66 μM, effectively blocking mRNA synthesis by inhibiting the guanylation of viral transcripts. Despite exhibiting moderate cytotoxicity (CC50 of 10.7 μM in HEp-2 cells), RSV L-protein-IN-5 shows significant antiviral activity in preclinical mouse models of RSV infection, making it a valuable tool for RSV research and therapeutic development. -
RSV Inhibitor
RSV-IN-5 is a potent dual inhibitor targeting respiratory syncytial virus (RSV) fusion proteins, effective against both wild-type and mutant strains. This compound demonstrates significant anti-RSV activity, with an EC50 of 2.0 nM against the wild-type A2 F protein and 8.1 nM against the D486N-mutant F protein. Its efficacy makes RSV-IN-5 a valuable tool in research focused on RSV-related therapeutics and understanding viral resistance mechanisms. -
RSV Inhibitor
Genkwanol C is a biflavonoid that serves as an inhibitor of respiratory syncytial virus (RSV). It demonstrates potent antiviral activity against RSV in vitro, making it a valuable tool for research on viral infections and potential therapeutic applications. Its mechanism of action offers insights into the interaction between flavonoids and viral pathogens. -
RSV Inhibitor
ent-11β-Hydroxyatis-16-ene-3,14-dione is a diterpenoid derived from the fresh roots of Euphorbia jolkinii, primarily targeting respiratory syncytial virus (RSV). This compound exhibits significant anti-RSV activity, making it a valuable tool for research in viral pathogenesis and therapeutic development focused on respiratory viral infections. Its role in inhibiting RSV positions it as a potential candidate for further exploration in antiviral research. -
RSV Polymerase Inhibitor
RSV L-protein-IN-4 is a noncompetitive inhibitor of the respiratory syncytial virus (RSV) polymerase, exhibiting an IC50 value of 0.88 μM. This compound demonstrates significant antiviral activity against various RSV strains, with an EC50 of 0.25 μM. RSV L-protein-IN-4 is essential for research into antiviral therapies targeting RSV infections. -
RSV Inhibitor
TP0591816 is a highly potent dual inhibitor targeting both wild-type and mutant respiratory syncytial virus (RSV) fusion proteins, exhibiting effective inhibition with EC50 values of 0.27 nM for wild-type and 0.70 nM for the D486N mutant. This compound demonstrates significant antiviral activity, making it a valuable tool for RSV research and potential therapeutic development. Researchers can utilize TP0591816 to explore mechanisms of RSV pathogenesis and evaluate antiviral strategies against this respiratory virus. -
RSV Inhibitor
BMS-433771 dihydrochloride hydrate is a selective inhibitor of respiratory syncytial virus (RSV), effectively targeting both RSV A and B strains. With an average EC50 of 20 nM, it demonstrates significant antiviral activity. This compound is valuable for research applications focused on respiratory tract diseases and the mechanisms underlying RSV infection and pathogenesis. -
RSV Polymerase Inhibitor
RSV L-protein-IN-2 is a noncompetitive inhibitor of the Respiratory Syncytial Virus (RSV) polymerase, exhibiting an IC50 value of 4.5 μM. This compound demonstrates significant antiviral activity against long strains of RSV, with an EC50 of 1.3 μM. It is applicable in research focused on developing therapeutic strategies against RSV infections and understanding viral replication mechanisms. -
RSV Inhibitor
BTA-9881 is a potent respiratory syncytial virus (RSV) inhibitor, demonstrating EC50 values of 48 nM, 59 nM, and 160 nM against RSV A2, RSV Long, and RSV B1, respectively. Its favorable pharmacokinetic properties make it a valuable reagent for studying RSV infection and evaluating potential antiviral therapies. BTA-9881 serves as an important tool in respiratory virus research, aiding in the development of effective treatments for RSV-related diseases. -
RSV Inhibitor
JNJ-7184 is a non-nucleoside inhibitor targeting the RSV-Large (L) polymerase. This compound exhibits potent antiviral activity, demonstrating a pEC50 of 7.86 and a pCC50 of 4.29 in HeLa cells. JNJ-7184 effectively prevents respiratory syncytial virus (RSV) replication and transcription by disrupting the initiation and early elongation stages of the viral life cycle, making it a valuable tool for research into RSV pathogenesis and potential therapeutic strategies. -
RSV Inhibitor
AZ-27 is a selective inhibitor of respiratory syncytial virus (RSV) by targeting its polymerase activity. This compound exhibits the ability to differentially suppress various RSV polymerase functions at the promoter level, effectively inhibiting the early stages of mRNA transcription and genome replication. AZ-27 is suitable for research applications focused on understanding RSV pathogenesis and developing antiviral strategies. -
RSV L protein Inhibitor
AZD4316 is an inhibitor of the respiratory syncytial virus (RSV) L protein, demonstrating significant antiviral activity against RSV A subtypes, including strain A2. This compound effectively hinders viral replication during the early stages of infection, particularly at the viral entry phase. However, its efficacy diminishes when administered 12-24 hours post-infection. AZD4316 is valuable for research focused on RSV infection mechanisms and potential therapeutic strategies. -
RSV Inhibitor
RSV-IN-13 is a selective inhibitor of respiratory syncytial virus (RSV) fusion protein, exhibiting antiviral activity. It demonstrates an EC50 of 444.2 nM against the RSV A2 strain, with a CC90 of 23.7 μM in HepG2 cells. By effectively blocking the entry of the virus into host cells, RSV-IN-13 serves as a valuable tool for research on RSV infection and pathogenesis. -
RSV Inhibitor
A 33903 is a selective inhibitor of respiratory syncytial virus (RSV) replication. It demonstrates significant antiviral activity against RSV, making it a valuable tool for researchers studying RSV infections and related therapeutic interventions. This reagent can facilitate investigations into viral pathogenesis and the development of antiviral strategies. -
RSV Inhibitor
4,5-O-Dicaffeoyl quinic acid methyl ester is a potent antiviral agent specifically targeting respiratory syncytial virus (RSV). It exhibits strong inhibitory activity with an IC50 value of 0.63 μg/mL, indicating effective suppression of viral replication. The compound's safety profile is substantiated by a CC50 of 118.68 μg/mL, supporting its potential use in research applications focused on RSV-related therapeutic strategies. -
SARS-CoV-2 3CL Protease Inhibitor
Ensitrelvir is a selective, non-covalent, and non-peptidic inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 13 nM. This compound has demonstrated significant antiviral activity against SARS-CoV-2, making it a valuable tool for research into COVID-19 treatments. It is particularly applicable in studies focused on viral replication and therapeutic interventions targeting coronavirus proteases. -
SARS-CoV-2 Inhibitor
Simnotrelvir is a potent inhibitor of SARS-CoV-2 3CLpro, demonstrating an IC50 value of 0.022 µM. This compound exhibits significant antiviral activity against SARS-CoV-2, making it a valuable tool in research focusing on COVID-19 treatment and prevention strategies. Its efficacy in inhibiting viral replication positions it as a critical reagent for investigations into therapeutic options for coronavirus infections. -
SARS-CoV-2 3CL Protease Inhibitor
Ensitrelvir fumarate is a non-covalent, non-peptidic inhibitor targeting the SARS-CoV-2 3CL protease, exhibiting an IC50 of 13 nM. This compound plays a critical role in the inhibition of viral replication by blocking a key enzymatic function essential for SARS-CoV-2 maturation. It is primarily utilized in research applications related to COVID-19 therapeutic development and the exploration of antiviral strategies. -
SARS-CoV-2 Mpro Inhibitor
(±)-Alliin is a compound derived from garlic, recognized for its potential inhibitory effects on the main protease of SARS-CoV-2 (Mpro). This compound demonstrates antiviral activity, making it a candidate for research aimed at understanding and combating SARS-CoV-2 replication and infection mechanisms. Its application in biochemical studies can contribute to the development of therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
Leritrelvir is an orally active inhibitor of the SARS-CoV-2 main protease, displaying a slow-tight binding mechanism with a Ki value of 8.6 nM. This compound is valuable for research focused on therapeutic strategies against COVID-19, demonstrating potential in the development of antiviral agents aimed at mitigating SARS-CoV-2 replication. Its efficacy as a protease inhibitor makes it a significant candidate for studying protease-related pathways and antiviral drug design. -
SARS-CoV-2 3C-like protease (3CLpro) Inhibitor
Secutrelvir is a potent inhibitor of the SARS-CoV-2 3C-like protease (3CLpro), demonstrating IC50 values of 0.655 nM and 0.697 nM. By forming a reversible covalent bond with the catalytic cysteine C145, Secutrelvir effectively inhibits viral replication, making it a valuable tool in combating SARS-CoV-2. Its efficacy against various SARS-CoV-2 variants supports its potential applications in research focused on coronavirus disease 2019 (COVID-19). -
SARS-CoV-2 Inhibitor
Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 24 nM against wild-type SARS-CoV-2 Mpro. By inhibiting viral polyprotein processing, it effectively disrupts viral replication. Pomotrelvir demonstrates broad antiviral activity against various SARS-CoV-2 variants, including Omicron, and shows an additive effect when co-administered with nucleoside analogs targeting viral RNA synthesis. It is primarily utilized in the research and development of antiviral therapeutics for COVID-19 caused by SARS-CoV-2 and its variants. -
SARS-CoV-2 Inhibitor
Iscartrelvir is a non-covalent inhibitor that targets the 3CLpro protein of SARS-CoV-2. This compound demonstrates potent inhibitory activity against multiple SARS-CoV-2 variants, including Alpha, Beta, Gamma, Delta, Lambda, and Omicron, as well as two other coronaviruses, SARS-CoV and MERS-CoV. Iscartrelvir is valuable for research applications focused on antiviral strategies and the study of coronavirus proteases. -
SARS-CoV-2 Membrane Protein Inhibitor
CIM-834 is an orally bioavailable inhibitor targeting the SARS-CoV-2 membrane protein. It effectively disrupts the assembly of infectious viral particles while preserving viral RNA synthesis. In preclinical studies, CIM-834 has demonstrated a capability to reduce viral titers in lung tissues of SCID mice and prevent the transmission of SARS-CoV-2 among Syrian hamsters. Additionally, it exhibits inhibitory effects on the replication of both SARS-CoV-2 variants and SARS-CoV, making it relevant for COVID-19 research applications. -
SARS-CoV-2 Inhibitor
MPI60 is a potent inhibitor of SARS-CoV-2 main protease (MPro), demonstrating significant antiviral activity and low cellular cytotoxicity. This compound exhibits high metabolic stability in vitro, making it a valuable tool for SARS-CoV-2 research and therapeutic development. Researchers can utilize MPI60 to explore the molecular mechanisms of viral replication and potential intervention strategies. -
SARS-CoV Inhibitor
GS-621763 is an orally bioavailable prodrug of GS-441524 that serves as a potent inhibitor of SARS-CoV-2. It demonstrates significant antiviral activity, effectively reducing viral load to undetectable levels in ferrets infected with SARS-CoV-2. This compound is valuable for research applications related to coronavirus pathogenesis and therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
Cichoriin is a potent inhibitor of SARS-CoV-2, targeting viral replication and entry into host cells. It demonstrates significant antiviral activity, making it a valuable candidate for research into therapies for severe COVID-19. This compound may facilitate studies on the pathogenesis of the virus and the development of effective treatment strategies. -
SARS-CoV-2 MPro Inhibitor
Mpro inhibitor N3 is a potent inhibitor of the SARS-CoV-2 main protease (MPro), demonstrating an EC50 value of 16.77 µM. This compound exhibits antiviral activity not only against SARS-CoV-2 but also against other coronaviruses, including HCoV-229E, FIPV, IBV, and MHV-A59. Its ability to inhibit viral replication makes it a valuable tool for research in antiviral drug development and coronavirus disease studies. -
SARS-CoV-2 Inhibitor
AT-9010 tetrasodium is a potent inhibitor of the nucleotidyltransferase (NiRAN) domain, crucial for the replication of SARS-CoV-2. This triphosphate active metabolite of AT-527 demonstrates significant antiviral activity by disrupting viral replication processes. Its application is primarily focused on research related to SARS-CoV-2 and the development of therapeutic interventions for COVID-19. -
SARS-CoV-2 PLpro Inhibitor
PF-07957472 is an orally active inhibitor of the SARS-CoV-2 papain-like protease (PLpro). It demonstrates significant antiviral activity, evidenced by an EC50 of 13.9 nM in SARS-CoV-2 infected normal human bronchial epithelial (NHBE) cells. Additionally, PF-07957472 exhibits protective effects in a mouse model adapted for COVID-19, making it a valuable reagent for studying antiviral mechanisms and therapeutic applications related to SARS-CoV-2 infection. -
SARS-CoV Replication Inhibitor
SSAA09E2 is an inhibitor of SARS-CoV replication, specifically targeting the early interactions between the SARS spike protein (S) and its receptor, Angiotensin Converting Enzyme-2 (ACE2). This compound exhibits significant antiviral activity, making it a valuable tool for research into therapeutic strategies against SARS-CoV infections. Its application in studying viral entry mechanisms and potential treatments provides critical insights into coronavirus-related diseases. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-13 is a potent inhibitor of SARS-CoV-2 with a reported IC50 of 0.057 μM. As a niclosamide analogue, it demonstrates enhanced stability in human plasma and liver S9 enzyme assays compared to its predecessor, which may lead to improved bioavailability and longer half-life upon oral administration. This compound is valuable for research applications focused on antiviral therapies and understanding SARS-CoV-2 inhibition mechanisms. -
HBV Inhibitor
Coclauril is a potent inhibitor of Hepatitis B virus (HBV) replication, acting primarily on hepatocytes. It demonstrates antiviral activity in human hepatoblastoma cell lines, with an EC50 value of 7.6 μg/mL. Coclauril is utilized in research to explore therapeutic strategies against HBV and to study the mechanisms of viral replication inhibition.
